Last reviewed · How we verify

NCT06812091

Human Microbiome Research and Development for Overcoming Pediatric Diseases

Recruiting now Last updated 6 February 2025
What this trial tests

trial in Human Microbiome in 500 participants. Currently enrolling.

Timeline
1 January 2022
Primary endpoint
1 January 2026
1 January 2030

Quick facts

Lead sponsorHanyang University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date1 January 2022
Primary completion1 January 2026
Estimated completion1 January 2030
Sites1 location across South Korea

Conditions studied

Sponsor

Hanyang University

Who can join

Eligibility, any sex, with Human Microbiome or Pediatrics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prediction and treatment of pediatric diseases and long-term outcomes through microbiome and multi-omics analysis by life cycle: We aim to demonstrate that a wide range of diseases are associated with gut microbiome dysbiosis and to investigate the subsequent recovery (restoration) or further deterioration of the gut microbiome over time. This study seeks to offer a novel perspective on changes in the gut microbiome, particularly in the context of the gut-lung and gut-brain axes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hanyang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06812091.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing